Sclerostin Downregulation Globally by Naturally Occurring Genetic Variants, or Locally in Atherosclerotic Plaques, Does Not Associate With Cardiovascular Events in Humans

Inhibition of sclerostin increases bone formation and decreases bone resorption, leading to increased bone mass, bone mineral density, and bone strength and reduced fracture risk. In a clinical study of the sclerostin antibody romosozumab versus alendronate in postmenopausal women (ARCH), an imbalan...

Descripción completa

Detalles Bibliográficos
Autores principales: Holdsworth, Gill, Staley, James R, Hall, Peter, van Koeverden, Ian, Vangjeli, Ciara, Okoye, Remi, Boyce, Rogely W, Turk, James R, Armstrong, Martin, Wolfreys, Alison, Pasterkamp, Gerard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360163/
https://www.ncbi.nlm.nih.gov/pubmed/33784435
http://dx.doi.org/10.1002/jbmr.4287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360163/
https://www.ncbi.nlm.nih.gov/pubmed/33784435
http://dx.doi.org/10.1002/jbmr.4287

Ejemplares similares